Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Excretion of [¹⁴C]MK-0616 in Healthy Participants
NCT06658626Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enlicitide in hypercholesterolemia, sponsored by Merck & Co. Primary endpoints: Cumulative Amount of Radioactivity Excreted in Urine up to 15 days, Cumulative Amount of Radioactivity Excreted in Feces up to 15 days and 8 more. Started Mar 2023; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06658626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06658626.